Pacific Biosciences (PACB) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
https://www.zacks.com/stock/news/2227228/pacific-biosciences-pacb-q4-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2227228
Feb 15, 2024 - While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
0
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
https://www.zacks.com/stock/news/2249871/reasons-to-retain-pacbio-pacb-stock-in-your-portfolio-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2249871
Apr 03, 2024 - PacBio's (PACB) strong product demand and top-line growth raise optimism about the stock.
0
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
https://www.zacks.com/stock/news/2227162/pacific-biosciences-of-california-pacb-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2227162
Feb 15, 2024 - Pacific Biosciences (PACB) delivered earnings and revenue surprises of 12.90% and 0.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
0
PacBio's (PACB) New Panel to Aid Its Clinical Research Solution
https://www.zacks.com/stock/news/2240028/pacbio-s-pacb-new-panel-to-aid-its-clinical-research-solution?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240028
Mar 13, 2024 - PacBio (PACB) announces the PureTarget repeat expansion panel, which is the HiFi long-read sequencing that supports comprehensive analysis of 20 genes associated with neurological diseases.
0
Pages: 1
Page 1